Onyx Pharmaceuticals Inc. won approval from U.S. regulators to sell the kidney cancer drug Nexavar for use against liver cancer.
Nexavar, marketed by Onyx (NASDAQ: ONXX) partner Bayer HealthCare Pharmaceuticals Inc., already is approved in more than 60 countries as a kidney cancer treatment. But the tablets are the first systemic therapy for liver cancer, giving Onyx/Bayer at least two years head start on potential competitors.
Liver cancer is the sixth-most common cancer, killing about 600,000 people annually. More than half of those deaths are in China, where Onyx is performing additional trials. The drug is also is undergoing further tests in Japan.
The tablet, which costs about $4,700 a month, is taken twice in the morning and twice at night.
-Onyx's Nexavar OK'd as liver cancer treatment